| pubmed-article:19483734 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19483734 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:19483734 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:19483734 | lifeskim:mentions | umls-concept:C0144576 | lld:lifeskim |
| pubmed-article:19483734 | lifeskim:mentions | umls-concept:C1506770 | lld:lifeskim |
| pubmed-article:19483734 | lifeskim:mentions | umls-concept:C0599894 | lld:lifeskim |
| pubmed-article:19483734 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:19483734 | lifeskim:mentions | umls-concept:C1521840 | lld:lifeskim |
| pubmed-article:19483734 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:19483734 | pubmed:dateCreated | 2009-6-1 | lld:pubmed |
| pubmed-article:19483734 | pubmed:abstractText | A randomized phase III trial evaluated the effect of adding lapatinib to paclitaxel as first-line therapy for patients with metastatic breast cancer whose tumors were negative or untested for human epidermal growth factor receptor 2 (HER2) overexpression. Progression-free survival was prolonged significantly in patients with HER2-overexpressing tumors, which indicates that lapatinib exerts its main effects via the HER2 pathway. | lld:pubmed |
| pubmed-article:19483734 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19483734 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19483734 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19483734 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19483734 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19483734 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19483734 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19483734 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19483734 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19483734 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:19483734 | pubmed:issn | 1759-4782 | lld:pubmed |
| pubmed-article:19483734 | pubmed:author | pubmed-author:GomezHenry... | lld:pubmed |
| pubmed-article:19483734 | pubmed:author | pubmed-author:CastañedaCarl... | lld:pubmed |
| pubmed-article:19483734 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19483734 | pubmed:volume | 6 | lld:pubmed |
| pubmed-article:19483734 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19483734 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19483734 | pubmed:pagination | 308-9 | lld:pubmed |
| pubmed-article:19483734 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:19483734 | pubmed:meshHeading | pubmed-meshheading:19483734... | lld:pubmed |
| pubmed-article:19483734 | pubmed:meshHeading | pubmed-meshheading:19483734... | lld:pubmed |
| pubmed-article:19483734 | pubmed:meshHeading | pubmed-meshheading:19483734... | lld:pubmed |
| pubmed-article:19483734 | pubmed:meshHeading | pubmed-meshheading:19483734... | lld:pubmed |
| pubmed-article:19483734 | pubmed:meshHeading | pubmed-meshheading:19483734... | lld:pubmed |
| pubmed-article:19483734 | pubmed:meshHeading | pubmed-meshheading:19483734... | lld:pubmed |
| pubmed-article:19483734 | pubmed:meshHeading | pubmed-meshheading:19483734... | lld:pubmed |
| pubmed-article:19483734 | pubmed:meshHeading | pubmed-meshheading:19483734... | lld:pubmed |
| pubmed-article:19483734 | pubmed:meshHeading | pubmed-meshheading:19483734... | lld:pubmed |
| pubmed-article:19483734 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19483734 | pubmed:articleTitle | Targeted therapies: Combined lapatinib and paclitaxel in HER2-positive breast cancer. | lld:pubmed |
| pubmed-article:19483734 | pubmed:affiliation | Division of Medicine, Instituto Nacional de Enfermedades Neoplásicas, Av. Angamos Este 2520, Surquillo, Lima 34, Peru. | lld:pubmed |
| pubmed-article:19483734 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19483734 | pubmed:publicationType | Comment | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19483734 | lld:pubmed |
